Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $2.03B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.03M
Average 1.23M
IMNM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Immunome, Inc.NASDAQ: IMNM
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $69.51M rose 41.3% year over year, ahead of the +35.6% change in trailing-twelve-month research & development. Sequentially, it rose 16.1% from the prior quarter. Over 3 fiscal years it compounded at +95.7% a year.
Context
- Research & development amounted to 2511.6% of revenue in FY2025, up 1078.8 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +41.3% holds above the trailing-twelve-month pace of +35.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 174.33M USD
- Year-over-year change
- +34.6%
- 4-year CAGR
- +87.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 174.33M | +34.6% |
| FY2024 | 2024-12-31 | 129.54M | +461.1% |
| FY2023 | 2023-12-31 | 23.09M | -0.8% |
| FY2022 | 2022-12-31 | 23.27M | +64.9% |
| FY2021 | 2021-12-31 | 14.11M | — |
Research & Development vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +35.6% is the 4th highest of 11, against a peer median of +22.3%.
- Over three fiscal years its annual growth of +95.7% compares with a peer median of +27.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $283.32M USD | +31.2% | +43.9% | 252960.7% | |
| LTM Mar 2026 | $259.11M USD | +17.2% | +34.4% | 67.2% | |
| LTM Sep 2026 | $236.54M USD | +35.6% | +95.7% | — | |
| LTM Mar 2026 | $230.13M USD | +16.7% | +43.3% | 362.4% | |
| LTM Mar 2026 | €201.11M EUR | +27.4% | +19.9% | 539.2% | |
| LTM Mar 2026 | $151.37M USD | -38.7% | +6.7% | 152.0% | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $129.68M USD | +5.2% | +71.4% | — | |
| LTM Mar 2026 | $37.44M USD | +64.5% | +11.3% | — | |
| LTM Sep 2026 | $23.16M USD | +47.2% | -19.1% | — | |
| LTM Mar 2026 | $20.26M USD | +102.3% | +57.1% | — | |
| Peer median (excluding IMNM) | — | +22.3% | +27.1% | 257.2% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$17.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.